Rumble

Rumble Bio is a biotechnology company that leverages generative artificial intelligence and synthetic biology to design and develop the next generation of programmable protein therapeutics. Founded by researchers from the MIT Media Lab and the Wyss Institute, the company utilizes a proprietary machine learning platform to engineer novel proteins and peptides with optimized therapeutic properties, such as enhanced specificity and potency. Rumble Bio's approach integrates advanced computational modeling with high-throughput experimental validation to accelerate the discovery of treatments for complex diseases. The company aims to transform drug discovery by creating highly precise protein-based medicines that address significant unmet medical needs.